Nordisk – Page 5 – Talk Bio

Actionable Insights Powered by AI

Novo Nordisk’s High-Dose Wegovy Demonstrates Superior Weight Loss of 20.7% in Phase IIIb Trial

9 months ago talkbio0Tagged Nordisk, Obesity, semaglutide, Step (specific stage), Trial Phase 3B, Up, Wegovy

Novo Nordisk, Wegovy, semaglutide, obesity treatment, weight loss, Phase IIIb trial, STEP UP trial

Novo Nordisk and Lilly Lead Clarivate’s 2025 ‘Drugs to Watch’ List with Breakthrough Therapies

10 months ago talkbio0Tagged blockbuster drugs, Clarivate, Drug Industry, Eli, Eli Lilly, gene therapy, Neoplasms, Nordisk, Obesity

Clarivate, Drugs to Watch 2025, Novo Nordisk, Eli Lilly, Obesity treatments, Gene therapy, Oncology, Blockbuster drugs, Pharmaceutical industry

Novo Nordisk and Valo Health Expand AI-Driven Collaboration to Develop Novel Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease

10 months ago talkbio0Tagged Artificial Intelligence, biotech, Cardiovascular Diseases, Computational Technique, Diabetes, Drug Development, Nordisk, Obesity, Valo Health

Novo Nordisk, Valo Health, AI, Obesity, Type 2 Diabetes, Cardiovascular Disease, Drug Development, Computational Biotech

Novo Nordisk and Variant Bio Collaborate on Metabolic Disease Research, Focusing on Diverse Populations

10 months ago talkbio0Tagged benefit-sharing program, Bio, Diversity, Genetic Research, geographic population, Metabolic Diseases, Nordisk, Variant, VB-Inference platform

Novo Nordisk, Variant Bio, Metabolic disease, Genetic research, Diverse populations, VB-Inference platform, Benefit-sharing program

Novo Nordisk Seeks FDA Restriction on Victoza Compounding Amid Ongoing GLP-1 Supply Issues

10 months ago talkbio0Tagged Glucagon-Like Peptide 1, liraglutide, Nordisk, pharmaceutical regulation, United States Food and Drug Administration, Victoza

Novo Nordisk, FDA, Victoza, liraglutide, compounding, GLP-1, supply issues, pharmaceutical regulation

Alhemo: A Breakthrough in Hemophilia Treatment – FDA Approves Novo Nordisk’s Once-Daily Prophylactic Injection for Hemophilia A and B with Inhibitors

10 months ago talkbio0Tagged Alhemo, Approved, concizumab, Hemophilia A and B, inhibitors, Nordisk, once-daily, Prophylactic treatment, United States Food and Drug Administration

Alhemo, Novo Nordisk, Hemophilia A and B, Inhibitors, FDA Approval, Once-Daily Prophylactic Treatment, Concizumab

Novo Nordisk’s CagriSema Falls Short of Weight Loss Expectations, Highlighting High Investor Expectations

10 months ago talkbio0Tagged CagriSema, Expectations, investor, Nordisk, Obesity, REDEFINE 1 trial, Weight-Loss Agents

CagriSema, Novo Nordisk, Weight Loss Drugs, REDEFINE 1 Trial, Obesity Treatment, Investor Expectations

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target

11 months ago talkbio0Tagged cagrilintide, CagriSema, Nordisk, Obesity, Phase 3 REDEFINE 1 Trial, semaglutide, Weight Loss

CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide

Novo Nordisk’s Vision for the Future of GLP-1 Therapies: Expanding Beyond Diabetes and Obesity

11 months ago talkbio0Tagged advancements, agonists, Chronic disease, Diabetes Mellitus, Non-Insulin-Dependent, Future, Glucagon-Like Peptide 1, Nordisk, Obesity, semaglutide

GLP-1 agonists, Novo Nordisk, Type 2 diabetes, Obesity, Future treatments, Chronic diseases, Semaglutide, Tirzepatide, Therapeutic advancements

Novo Nordisk and Photys Therapeutics Collaborate on Novel Proximity-Based Therapeutics for Cardiometabolic Diseases

11 months ago talkbio0Tagged cardiometabolic diseases, Nordisk, PHICS, proximity-based, research collaboration, Technology

Novo Nordisk, Photys Therapeutics, Cardiometabolic diseases, Proximity-based therapeutics, PHICS technology, Research collaboration